Peter Jezzard
University of Oxford, UK
2020

Peter Jezzard is the Herbert Dunhill Professor of Neuroimaging at the University of Oxford. He trained as an undergraduate in physics at the University of Manchester in the UK, before commencing a Ph.D. in magnetic resonance physics at the University of Cambridge. In 1991 he moved to the National Institutes of Health, USA, to take up a post-doctoral, and later Unit Chief, position. He remained there for seven years, working in the NHLBI and NIMH, mostly on projects related to the development of functional MRI and physiological MRI measurements in the brain. In 1998 he moved back to the UK where he became a founding member of the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (now the Wellcome Centre for Integrative Neuroimaging). Initially a member of the MRC External Scientific Staff, seconded to Oxford, he was appointed to a tenured university professorship in neuroimaging in 2003, and to a fellowship at University College Oxford.

He has served in a number of capacities for the International Society for Magnetic Resonance in Medicine (ISMRM), including as President of the Society from 2013-2014, and as Editor-in-Chief of the ISMRM’s main methodological journal, Magnetic Resonance in Medicine, since January 2020. He was made a Fellow of the ISMRM in 2008, and is also a Fellow of the UK Institute of Physics. Dr. Jezzard has served in a number of graduate studies leadership roles in Oxford, including as Chair of the Medical Sciences Division Graduate Studies Committee, Chair of the University’s Graduate Admissions Committee, and Dean of Graduates for University College. He has also served as Director of the Oxford-Nottingham EPSRC & MRC Centre for Doctoral Training in Biomedical Imaging, which has trained over 50 physical science graduate students in a wide variety of biomedical imaging from light microscopy to human radiological sciences. He has authored or co-authored over 200 scientific papers in the area of biomedical magnetic resonance, and has a particular interest in developing methods for application in cerebrovascular disease, and in developing methods for high field (7 Tesla) human imaging.